Clinical Trials

Inclusion Criteria:

• Must be ≥ 18 years of age at the time of obtaining informed consent.
• Eastern Cooperative Oncology Group performance status of 0 or 1 at screening -Must have at least one PET-avid measurable lesion according to Modified Lugano Criteria.
• Confirmed histological diagnosis of active relapse/refractory cHL.
• Must have failed at least 2 prior lines of systemic therapy. 
• No previous treatment with anti-TIM-3.
• Adequate organ and bone marrow function measured within 7 days prior to first dose.
• Non-pregnant women and willingness of female patients to avoid pregnancy or male participants willing to avoid fathering children through highly effective methods of contraception.

Exclusion Criteria:

• Unresolved toxicities of ≥ Grade 2 from prior therapy.
• Any prior ≥ Grade 3 imAE while receiving immunotherapy.
• Patients with CNS involvement or leptomeningeal disease.
• History of organ transplantation (e.g., stem cell or solid organ transplant).
• Any venous or arterial thromboembolic event within ≤ 6 months prior to the first dose of study intervention.
• Active infection including TB, HIV, hepatitis A, chronic or active hepatitis B, chronic or active hepatitis C, active COVID-19 infection
• History of arrhythmia which is requires treatment; symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia.
• Uncontrolled intercurrent illness.
• Active or prior documented autoimmune or inflammatory disorders.
• Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active ILD.
• Other invasive malignancy within 2 years prior to screening.
• Congenital long QT syndrome or history of QT prolongation associated with other medications that cannot be changed or discontinued based on a cardiologist assessment.
• Current or prior use of immunosuppressive medication within 14 days prior to the first dose of study intervention.
• Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment.